Patient appointments
New symptoms and slow improvement can be worrying. A useful review separates disease activity, possible medicine effects and urgent problems. Your diagnosis and treatment phase matter when interpreting both benefits and risks.
An appointment does not confirm access to a particular medicine, procedure or specialist. Ask the team about the care and coverage you need.
Medical information checked against current US sources: October 19, 2026.
TREMFYA can increase infection risk. The label also warns about serious allergic reactions, TB and liver injury. Complete the recommended TB evaluation and vaccination review before treatment. Do not start during a clinically important active infection until the clinician determines it has resolved or is adequately treated.
For Crohn’s disease or ulcerative colitis, liver enzymes and bilirubin are checked before treatment, for at least 16 weeks and periodically afterward. For psoriasis or psoriatic arthritis, baseline and periodic liver tests are recommended when clinically indicated. Report liver disease and all other medicines.
The label lists reactions such as respiratory infections, headache and injection-site reactions. Other reported reactions depend on the condition and study population; fatigue and abdominal symptoms appear in bowel-disease studies. Trial percentages from different diseases or medicines should not be compared as if the studies were identical.
Describe the symptom, severity, date of the dose and any fever, breathing symptoms, bowel change or effect on daily activity. Persistent fatigue, joint pain, diarrhea or an unusual rash deserves review. Do not assume it is simply a temporary adjustment because another patient described it online.
Breathing difficulty, throat or face swelling, fainting or other signs of a severe allergic reaction need emergency help. Contact the treating team promptly for signs of an important infection or possible liver injury, such as yellow skin or eyes or dark urine.
If bowel disease is worsening, severe pain, substantial bleeding, persistent vomiting or dehydration needs prompt medical assessment. If joint disease is worsening, report swelling and loss of function. Do not wait for a scheduled treatment milestone when you are becoming unwell.
Psoriasis trials assessed skin response at week 16; adult psoriatic-arthritis trials assessed joint response at week 24. Bowel-disease trials used their own induction and maintenance endpoints. These are research assessment times, not a promise of improvement or an instruction to wait that long before contacting the clinician.
Agree on a review calendar and measures that fit your diagnosis: plaques and itch, joint swelling and function, or bowel symptoms plus objective inflammation tests. If benefit is insufficient, the clinician can reassess the diagnosis, adherence, safety and treatment choice. Do not increase a dose or shorten the interval yourself.
Neither is listed among the common adverse reactions in the current US label. That does not rule out an individual reaction or establish why a change occurred. Report timing, amount of weight change, swelling, hair shedding, scalp symptoms and other medicines. Significant or persistent changes deserve assessment.
There is no single reliable duration. The cause, severity, condition and treatment phase matter. A mild local reaction and a serious infection need different responses. Persistent, worsening or severe symptoms should be assessed rather than managed by waiting for a number of days or the next injection.
The current US prescribing information has no boxed warning. That does not mean it is risk-free or prove the absence of any possible cancer risk. Discuss a cancer history and individual concerns with the treating clinician. The prominent labeled precautions include allergic reactions, infections, TB, liver injury and live vaccines.
Complete age-appropriate vaccines before starting when possible. The label advises avoiding live vaccines during treatment. Tell the vaccinating clinician about TREMFYA and ask the prescriber which vaccine and timing fit your situation. Do not independently stop treatment to receive a vaccine.
Human data are insufficient to establish pregnancy risk, and information about effects during breastfeeding is limited. Discuss pregnancy plans or a new pregnancy promptly with the prescriber and obstetric team. Do not assume that a forum experience proves safety or that stopping automatically carries less risk than continuing.
Skin response and joint response are separate outcomes. Persistent stiffness, swelling or declining function needs review of the joint diagnosis and treatment plan. Do not use skin clearance alone to decide that psoriatic arthritis is controlled.
Contact the prescribing team before the next dose if you have a clinically important infection or concerning symptoms. The label directs clinicians to withhold treatment for important infections until they resolve. Your team should decide what that means for the illness and schedule you have; do not create a new interval yourself.
Choose a service and clinic in the Nao booking app. Confirm appointment availability and the care you need with the team.